Jounce Therapeutics Performance
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 1.01, which attests to a somewhat significant risk relative to the market. Jounce Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Jounce Therapeutics is expected to follow. Jounce Therapeutics right now retains a risk of 0.0%. Please check out Jounce Therapeutics downside variance, and the relationship between the maximum drawdown and skewness , to decide if Jounce Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Jounce Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Jounce Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 96.8 M | |
| Total Cashflows From Investing Activities | 83.5 M |
Jounce |
Jounce Therapeutics Relative Risk vs. Return Landscape
If you would invest 188.00 in Jounce Therapeutics on January 26, 2024 and sell it today you would earn a total of 0.00 from holding Jounce Therapeutics or generate 0.0% return on investment over 90 days. Jounce Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Jounce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Jounce Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Jounce Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Jounce Therapeutics, and traders can use it to determine the average amount a Jounce Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| JNCE |
Based on monthly moving average Jounce Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Jounce Therapeutics by adding Jounce Therapeutics to a well-diversified portfolio.
Jounce Therapeutics Fundamentals Growth
Jounce Stock prices reflect investors' perceptions of the future prospects and financial health of Jounce Therapeutics, and Jounce Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Jounce Stock performance.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Price To Earning | 10.76 X | |||
| Price To Book | 0.27 X | |||
| Price To Sales | 7.27 X | |||
| Revenue | 82 M | |||
| EBITDA | (50.16 M) | |||
| Cash And Equivalents | 148.56 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.89 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 3.54 X | |||
| Cash Flow From Operations | (28.88 M) | |||
| Earnings Per Share | (0.96) X | |||
| Total Asset | 212.55 M | |||
| Retained Earnings | (292.79 M) | |||
| Current Asset | 103.95 M | |||
| Current Liabilities | 51.26 M | |||
About Jounce Therapeutics Performance
To evaluate Jounce Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Jounce Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Jounce Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Jounce Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Jounce's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 137 people.Things to note about Jounce Therapeutics performance evaluation
Checking the ongoing alerts about Jounce Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Jounce Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Jounce Therapeutics is not yet fully synchronised with the market data | |
| Jounce Therapeutics may become a speculative penny stock | |
| Jounce Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82 M. Net Loss for the year was (50.92 M) with profit before overhead, payroll, taxes, and interest of 27.2 M. | |
| Jounce Therapeutics currently holds about 148.56 M in cash with (28.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 85.0% of the company shares are owned by institutional investors |
- Analyzing Jounce Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Jounce Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Jounce Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Jounce Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Jounce Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Jounce Therapeutics' stock. These opinions can provide insight into Jounce Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |